18 May 2007
Palliative percutaneous kidney embolization with enbucrilate in patients with renal cell carcinoma: Safety and symptom control
Zbigniew Serafin, Maciej Karolkiewicz, Piotr Strześniewski, Władysław Lasek, Michał Bryczkowski, Zbigniew WolskiMed Sci Monit 2007; 13(1): 98-104 :: ID: 482390
Abstract
Background: Primarily palliative renal embolization is a relatively rare procedure which is indicated in patients with unresectable kidney malignancies and in patients in poor general condition. The aim of this paper was to evaluate the role of primarily palliative transarterial renal embolization for the treatment of inoperable patients with renal cell carcinoma, assessing the indications, safety, and efficacy of this procedure.Material and Methods: Seventy-three patients scheduled for palliative embolization between 1998 and 2005 were retrospectively analyzed regarding their medical history, the procedure report, and data from the early postoperative period. Results: Sixty-six of the 73 patients presented with renal cell carcinoma stage IV. The most common indication for embolization was hematuria (34%), followed by flank pain (32%), prophylaxis in stage IV (25%), lack of consent for surgery (7%), and poor general condition (3%). Embolizations were performed under local anesthesia with a mixture of enbucrilate and iodinated oil, with the use of additional embolizing materials in two cases. The procedure eliminated hematuria in 100% of cases and removed the loin pain completely in 72%. Migration of the embolizing material was observed in 10% of cases, and in 4% it resulted in symptomatic occlusion of the lower extremity distal arteries. Postembolic syndrome was noted in 92% of the patients. Conclusions: Percutaneous palliative embolization with enbucrilate is a safe and effective method of treating patients with unresectable renal cell carcinoma. The potential effect of the embolization on cancer progression and improvement of survival in these patients still requires prospective investigation.
Keywords: Aged, 80 and over, Carcinoma, Renal Cell - therapy, Embolization, Therapeutic, Enbucrilate - therapeutic use, Kidney - pathology
Editorial
01 June 2025 : Editorial
Editorial: Harmonization and Publication of the 2025 Updates of the CONSORT and SPIRIT Statements for Clinical TrialsDOI: 10.12659/MSM.949923
Med Sci Monit 2024; 31:e949923
In Press
Database Analysis
Predictive Value of Anion Gap for Acute Kidney Injury Progression and OutcomesMed Sci Monit In Press; DOI: 10.12659/MSM.947405
Clinical Research
Outcomes from Quantitative Flow Ratio-Guided Complete Revascularization and Angiography-Guided Percutaneous...Med Sci Monit In Press; DOI: 10.12659/MSM.948085
Clinical Research
Impact of Tirofiban and Cilostazol on Cardiac Recovery in Elderly Patients with Acute Coronary SyndromeMed Sci Monit In Press; DOI: 10.12659/MSM.947831
Clinical Research
Effects of Weight Loss on Insulin Resistance and Liver Health in T2DM and NAFLD PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.947157
Most Viewed Current Articles
17 Jan 2024 : Review article 9,036,342
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 703,927
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 32,468
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 26,520
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912